Lymphoplasmacytic lymphoma with the <i>MYD88</i><sup>L265P</sup> mutation, producing non-IgM monoclonal immunoglobulins: 4 case reports
-
- Nakayama Yoichi
- Department of Hematology, Tenri Hospital Department of General Internal Medicine, Tenri Hospital
-
- Iioka Futoshi
- Department of Hematology, Tenri Hospital
-
- Toda Yusuke
- Department of Hematology, Tenri Hospital
-
- Maruyama Wataru
- Department of Hematology, Tenri Hospital
-
- Nagai Yuya
- Department of Hematology, Tenri Hospital
-
- Akasaka Takashi
- Department of Hematology, Tenri Hospital
-
- Maekawa Fumiyo
- Tenri Institute of Medical Research
-
- Hayashida Masahiko
- Tenri Institute of Medical Research
-
- Honjo Gen
- Department of Diagnostic Surgical Pathology, Tenri Hospital
-
- Ohno Hitoshi
- Department of Hematology, Tenri Hospital Tenri Institute of Medical Research
Bibliographic Information
- Other Title
-
- <i>MYD88</i><sup>L265P</sup> 遺伝子変異を認めたnon-IgMリンパ形質細胞リンパ腫(LPL)の4症例
- Lymphoplasmacytic lymphoma with the MYD88[L265P] mutation, producing non-IgM monoclonal immunoglobulins : 4 case reports
Search this article
Abstract
<p>We herein present four cases of bone marrow (BM)-based B-cell neoplasms, which had non-IgM class M-proteins and carried the MYD88L265P mutation. Patients were in their fifties to eighties and were all male. Their presenting symptoms as well as routine laboratory test values were variable, and none had osteolytic bone lesions, renal insufficiency, or hypercalcemia or any signs or symptoms indicative of hyperviscosity. M-proteins in the serum of each case were IgG-κ and small amounts of IgM-κ in 1, IgG-κ in 2, and light chain λ only in 1, and Bence Jones protein was detected in the urine of 3. BM showed hypercellularity with the infiltration of 22.4-93.9% mature lymphocytes and cells with the plasmacytoid/plasma cell appearance were found in 2. Flow cytometry showed that neoplastic cells were uniformly positive for CD19, CD20, and CD22 and negative for CD5 and CD23. Increased numbers of mast cells were detected in 2 cases, while Dutcher bodies were observed in a few plasma cells in 1. We developed two polymerase chain reaction (PCR)-based tests to detect the MYD88L265P mutation and obtained PCR products indicative of the mutation in all four cases. Each patient was treated with rituximab alone or in combination with fludarabine or bendamustine, or bortezomib and dexamethasone. Although each case was formerly diagnosed with variable diseases, the presence of the MYD88L265P mutation indicated that all 4 cases were reliably classified into the category of lymphoplasmacytic lymphoma.</p>
Journal
-
- Tenri Medical Bulletin
-
Tenri Medical Bulletin 22 (1), 12-28, 2019-12-25
Tenri Foundation, Tenri Institute of Medical Research
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001288155168640
-
- NII Article ID
- 130007686991
-
- NII Book ID
- AA11350134
-
- ISSN
- 21872244
- 13441817
-
- NDL BIB ID
- 030187056
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed